Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
Open Access
- 1 March 2016
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 15 (1) , 1-13
Abstract
Several antidiabetic drugs (i.e., sulfonylureas; SU, rosiglitazone) have been reported to be associated with increased risks of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 inhibitors (DPP4i) are newly available antidiabetic drugs. Most studies only compared DPP4i with a placebo or SU, or targeted a specific CVD event of interest (i.e., heart failure; HF). Comparative research of CVD risks of DPP4i with other antidiabetic drugs (i.e., metformin, thiazolidinediones, meglitinides, acarbose, and insulin) remains scarce. This study was aimed to assess comparative risks of CVD, including ischemic stroke, myocardial infarction (MI) and HF, and hypoglycemia of DPP4i with other antidiabetic drugs. We utilized Taiwan’s National Health Insurance Research Database. A total of 123,050 T2DM patients newly prescribed oral antidiabetic treatments were identified in 2009–2010 and followed until 2013. Outcome endpoints included a composite of CVD events: hospitalizations for ischemic stroke, MI and HF, and hypoglycemia. Time-varying Cox proportional hazards regression was applied to assess the time to event hazards of various antidiabetic drugs, adjusted for patients’ demographics, comorbidity, diabetic complications, and co-medications. Additional analyses were performed for the patients with and without CVD history, respectively. DPP4i users had significantly lower CVD risks as compared to that of non-DPP4i users (adjusted hazard ratio [aHR]: 0.83, 95 % confidence interval [CI]: 0.76–0.91). Compared to DPP4i users, meglitinides (aHR 1.3, 95 % CI 1.20–1.43) and insulin users (aHR 3.73, 95 % CI 3.35, 4.14) had significantly higher risks for composite CVD, as well as those for stroke, MI, HF, and hypoglycemia. Additionally, metformin users had significantly lower risks for composite CVD risk (aHR 0.87, 95 % CI 0.79–0.94), as well as those for MI, HF, and hypoglycemia, as compared to those of DPP4i users. Although there was a trend toward low CVD risks in pioglitazone users, the role of potential confounding by indication cannot be excluded. DPP4i-treated T2DM patients had lower risks for CVD as compared to those for non-DPP4i users, except metformin users.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (NSC 104-2320-B-006-008-MY3)
This publication has 52 references indexed in Scilit:
- Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary reportCardiovascular Diabetology, 2014
- Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort StudyCerebrovascular Diseases, 2013
- Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care DataPLOS ONE, 2011
- A web server for predicting inhibitors against bacterial target GlmU proteinBMC Pharmacology, 2011
- Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitusPharmacoepidemiology and Drug Safety, 2011
- Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance databaseBMC Clinical Pharmacology, 2011
- Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesBMJ, 2011
- Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative studyCardiovascular Diabetology, 2010
- Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort studyCardiovascular Diabetology, 2010
- Association between serious ischemic cardiac outcomes and medications used to treat diabetesPharmacoepidemiology and Drug Safety, 2008